Stockscreener 앱 받기
1.56
7.14%
-0.12
시간 외 거래:
1.56
전일 마감가:
$1.68
열려 있는:
$1.66
하루 거래량:
395.39K
Relative Volume:
0.04
시가총액:
$12.86M
수익:
$2.00M
순이익/손실:
$-11.43M
주가수익비율:
-0.7971
EPS:
-1.957
순현금흐름:
$-10.05M
1주 성능:
-9.30%
1개월 성능:
-27.78%
6개월 성능:
-39.06%
1년 성능:
-49.84%
1일 변동 폭
$1.48
$1.68
1주일 범위
$1.48
$1.77
52주 변동 폭
$1.48
$12.37
Lipocine Inc Stock (LPCN) Company Profile
명칭
Lipocine Inc
전화
801 994 7383
주소
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
1.56 | 12.86M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 재개 | H.C. Wainwright | Buy |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
| 2015-06-23 | 개시 | Canaccord Genuity | Buy |
모두보기
Lipocine Inc 주식(LPCN)의 최신 뉴스
Press Releases about Lipocine Inc.Common Stock (Nasdaq:LPCN) - FinancialContent
Lipocine Inc. (LPCN) stock price, news, quote and history - Yahoo Finance Singapore
Here's Why You Should Add LPCN Stock to Your Portfolio Now - TradingView
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - TradingView
Lipocine LPCN Rallies As BLOOM Phase 3 Trial Kicks Off - StocksToTrade
Lipocine (LPCN) Advances BLOOM Trial As Traders Eye Cash Runway - Timothy Sykes
Lipocine Shares Surge 30% After Health Canada Clears Oral Testosterone Drug - BigGo Finance
LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off - StocksToTrade
Lipocine Surges After Canada Approves TLANDO - Quiver Quantitative
Why Is Lipocine Stock Soaring Today?Lipocine (NASDAQ:LPCN) - Benzinga
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market - Yahoo Finance
Lipocine stock surges 30% on Health Canada drug approval - Yahoo Finance
LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off - www.timothysykes.com
LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes
Hecla Mining, XPO, Lipocine - TradingView
Lipocine stock surges 30% on Health Canada drug approval - Investing.com
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today - Stocktwits
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today - Yahoo Finance
LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off - StocksToTrade
Health Canada approves Lipocine’s testosterone therapy drug By Investing.com - Investing.com India
Health Canada approves Lipocine's oral testosterone drug TLANDO - StreetInsider
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy - PR Newswire
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy - Nasdaq
Lipocine (LPCN) Jumps As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes
Lipocine (LPCN) Jumps As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes
LPCN Jumps As Lipocine Launches Phase 3 BLOOM Trial - StocksToTrade
Health Canada approves Tlando oral testosterone therapy from Lipocine - StreetInsider
Lipocine Inc. (LPCN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lipocine Inc. (LPCN) stock price, news, quote and history - Yahoo Finance UK
Form 4 Lipocine Inc For: 1 October By Investing.com - Investing.com Nigeria
Lipocine director John Higuchi buys $55,042 in company stock By Investing.com - Investing.com South Africa
Lipocine director John Higuchi buys $55,042 in company stock By Investing.com - Investing.com Nigeria
Lipocine director John Higuchi buys $55,042 in company stock - Investing.com
Lipocine director John Higuchi buys $27,131 in company stock - Investing.com
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Lipocine stock price target maintained at $4 by H.C. Wainwright - Investing.com
Lipocine (NASDAQ: LPCN) shares slides from New York investor conference - Stock Titan
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PR Newswire
Lipocine launches BLOOM Phase 3 study of LPCN 1154 for PPD; plans ~120 patients, expects $1M/mo cash use - TradingView
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Australia
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Nigeria
Lipocine Cuts ATM Sales Agent Fee to Up to 3.0% - minichart.com.sg
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Canada
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com South Africa
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com India
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com Canada
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com
Lipocine Updates Sales Agreement Fee Structure with A.G.P. - TipRanks
Lipocine (LPCN) sets sales agent commissions at up to 3% - Stock Titan
Lipocine Inc (LPCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lipocine Inc 주식 (LPCN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Sep 29 '26 |
Buy |
2.15 |
9,037 |
19,430 |
225,395 |
| Higuchi John W. | Director |
Sep 28 '26 |
Buy |
2.16 |
12,561 |
27,132 |
216,358 |
| Higuchi John W. | Director |
Apr 07 '26 |
Buy |
2.03 |
40,000 |
81,200 |
203,797 |
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
4.22%
자본화:
|
볼륨(24시간):